Dogwood Therapeutics, Inc. (DWTX) Stock Price & Analysis
Dogwood Therapeutics, Inc. (DWTX) fell 2.60% to USD 1.5 as of July 25, 2026 at 05:04 UTC, according to Nexqual real-time market data.
DWTX last closed at USD 1.54; the session ranged USD 1.48–1.57 on volume of 17,884 shares. Market capitalization is $50.44M, with a 52-week range of USD 1.28–9.5 (NCM). Source: Nexqual, July 25, 2026 at 05:04 UTC.
Key Statistics (as of July 25, 2026 at 05:04 UTC)
| Price | USD 1.5 |
|---|---|
| Change | ▼ 2.60% (down) |
| Previous Close | USD 1.54 |
| Open | USD 1.54 |
| Day Range | USD 1.48 – 1.57 |
| 52-Week Range | USD 1.28 – 9.5 |
| Volume | 17,884 shares |
| Market Cap | $50.44M |
| Exchange | NCM |
Technical Analysis (DWTX)
Nexqual's technical model rates DWTX "NEUTRAL" based on 2 bullish and 3 bearish signals across 125 daily candles, as of July 25, 2026 at 05:04 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 53.07 (neutral) |
| vs SMA50 | Below (USD 1.57) |
| MACD | -0.03 (negative) |
Analyst Ratings (DWTX)
Wall Street analysts rate DWTX "None" based on 3 analysts, with a mean price target of USD 14 (range USD 12–15), per Nexqual as of July 25, 2026 at 05:04 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 14 |
| High Target | USD 15 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (DWTX)
| Next Earnings Date | 2026-05-14 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.15 vs est -0.2 ▲ beat |
| 2025-12-31 | USD -0.26 vs est -0.86 ▲ beat |
| 2025-09-30 | USD -8.2 vs est -1.58 ▼ miss |
| 2025-06-30 | USD -1.99 vs est -1.9 ▼ miss |
Source: Nexqual, July 25, 2026 at 05:04 UTC.
Financials & Fundamentals (DWTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -34.67% |
| Debt / Equity | 0.18 |
| Current Ratio | 5.86 |
| Total Cash | $13.23M |
| Total Debt | $144,930 |
| Free Cash Flow | $-17.26M |
Source: Nexqual, July 25, 2026 at 05:04 UTC.
Financial Health Score (DWTX)
Nexqual rates Dogwood Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 05:04 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $13M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$16M |
| Efficiency | Critical — ROE -35%, ROA -18.6% |
Ownership (DWTX)
| Insider Ownership | +73.35% |
|---|---|
| Institutional Ownership | +10.97% |
| Shares Outstanding | 33.63M |
| Float | 5.30M |
| Short % of Float | +0.82% |
Source: Nexqual, July 25, 2026 at 05:04 UTC.
Leadership (DWTX)
Dogwood Therapeutics, Inc. is led by Gregory Duncan (age 60), Chairman & CEO, per Nexqual as of July 25, 2026 at 05:04 UTC.
| Chairman & CEO | Gregory Duncan (age 60) |
|---|---|
| CFO, Secretary & Treasurer | Angela Walsh (age 58) |
| Senior Vice President of Operations | Ralph D. Grosswald M.P.H. (age 56) |
| Chief Scientific Advisor | Carol Duffy |
Major Backers & Investors (DWTX)
Notable institutional backers of Dogwood Therapeutics, Inc. include Armistice Capital, LLC, Fidelity, according to Nexqual as of July 25, 2026 at 05:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 9.75% |
| Fidelity | 0.22% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.97% |
| Geode Capital | 0.24% |
Source: Nexqual, July 25, 2026 at 05:04 UTC.
From Dogwood Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SLXN | Silexion Therapeutics Corp | USD 2.27 | ▼ 9.92% |
| NVNI | Nvni Group Limited | USD 1.13 | ▼ 4.24% |
| AIFF | Firefly Neuroscience, Inc. | USD 1.11 | ▼ 1.77% |
| ACON | Aclarion, Inc. | USD 2.42 | ▼ 5.1% |
| PLRZ | Polyrizon Ltd. | USD 14.68 | ▲ 2.02% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:04 UTC. This page is informational and not investment advice.